Agenus | AGEN - Sales Revenues


Agenus reported $34.2M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Agenus USD 34.2M 3.97M Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Celldex Therapeutics USD 15K 106K Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.27B 240M Mar/2026
Intrexon USD 717K 511K Jun/2024
J&J USD 24.1B 500M Mar/2026
Jiangsu Hengrui CNY 8.14B 300M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
Merck EUR 5.13B 120M Mar/2026
Merck USD 16.29B 110M Mar/2026
Northwest Biotherapeutics USD 200K 245K Sep/2025
Novartis USD 13.11B 226M Mar/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 139.07M 1.53M Mar/2026